An article about clinical-trial analyses examining how a novel Alzheimer’s treatment affected neuropsychiatric symptoms and caregiver distress, offering context and implications.
Key Takeaways
- Atuzaginstat showed significant Neuropsychiatric Inventory improvements in agitation and aggression after 48 weeks
- Treatment also produced significant reductions in caregiver distress in p
- No significant neuropsychiatric benefit was observed in p